Document is current

Article History

Accepted: 23 June 2024

First Online: 23 August 2024

Declarations

:

: There was no funding or financial assistance received for the development of this article.

: Hirra A. Chaudhary declares no potential competing interests. Timothy Cannon is a paid Molecular Tumor Board member for Intermountain Health. He has not had any other consulting in 2022. In 2021, he consulted for Bayer and Deciphera (both less than $5000). Arthur Winer has ownership stock in Sciencella Honoraria, HalioDx, and OncLive.

: This was a retrospective review of patients reviewed in our Molecular Tumor Board, which is under an institutional review board-approved protocol.

: Not applicable.

: Not applicable.

: The data that support the findings of the study are available on request from the corresponding author.

: Not applicable.

: HC: collection and assembly, manuscript writing. TC: conception and design, manuscript writing. AW: conception and design, manuscript writing. All authors approved the final version of the manuscript.